MRNA is trading at $36.89 (+3.45%) following Tuesday's 10.9% surge, driven by the filing for approval of its seasonal flu vaccine (mRNA-1010) in major markets and the announcement of $1B in extra cost cuts.
- Analyst actions were mixed: BofA raised its price target to $24 (still Underperform), while UBS issued a modest cut to $34 (Neutral).
- Investor focus remains heavily weighted toward pipeline progress, specifically RSV expansion and 2026 oncology catalysts.
- The stock is currently outperforming the mixed broader market (Nasdaq +0.44%).